In recent years, the emergence of novel therapeutic options that target the mutantBRAF downstream enzyme MEK has shown promising results in metastatic melanoma(11) and other cancers.However, resistance to BRAF inhibitors (e.g., dabrafenib) as monotherapy in treatingmelanoma has been observed, and strategies involving combination therapy (BRAFinhibitors [dabrafenib] and MEK inhibitors [trametinib]) show promise (12). This evidence concerns the gene BRAF and cancer.